News for Regeneron Pharmaceuticals Inc - Google Finance

Regeneron Pharmaceuticals Inc (REGN), Ampio Pharmaceuticals, Inc. (AMPE ...

Mon, 17 Jun 2013 12:31:52 GMT

Regeneron Pharmaceuticals Inc (REGN), Ampio Pharmaceuticals, Inc. (AMPE ...
Insider Monkey (blog) - Jun 17, 2013

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there's a slight pullback the stock shoots higher.

Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual ...

Tue, 11 Jun 2013 19:14:44 GMT

Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual ...
Seeking Alpha - Jun 11, 2013

Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 08:40 AM.

Biotechs Lose Ground As Achillion Pharmaceuticals, Inc. (ACHN) Takes a Dive

Mon, 17 Jun 2013 12:31:51 GMT

Biotechs Lose Ground As Achillion Pharmaceuticals, Inc. (ACHN) Takes a Dive
Insider Monkey (blog) - Jun 17, 2013

Fellow major biotech stock Regeneron Pharmaceuticals Inc (NASDAQ:REGN) lost 5% during the week, part of a sustained 15% slump over the past month.

Regeneron Pharmaceuticals Inc. (REGN), GlaxoSmithKline plc (GSK): The First ...

Wed, 12 Jun 2013 15:52:07 GMT

Regeneron Pharmaceuticals Inc. (REGN), GlaxoSmithKline plc (GSK): The First ...
Insider Monkey (blog) - Jun 12, 2013

Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are developing dupilumab to cure moderate to severe allergic asthma.

Regeneron Pharmaceuticals, Inc: How Big Can Eylea Get?

Tue, 28 May 2013 04:37:37 GMT

Regeneron Pharmaceuticals, Inc: How Big Can Eylea Get?
iStockAnalyst (press release) - May 28, 2013

(By Mani) Eylea is the main profit and growth driver for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Eylea is used to treat age-related wet macular degeneration (AMD), a condition that affects a tiny part of the retina at the back of the eye.

VIVUS Inc. (NASDAQ:VVUS), Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Tue, 28 May 2013 17:47:07 GMT

VIVUS Inc. (NASDAQ:VVUS), Regeneron Pharmaceuticals, Inc. (NASDAQ ...
SBWire (press release) - May 28, 2013

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally is ...

Is Biogen Idec Inc. (BIIB) Going to Burn These Hedge Funds? - Insider Monkey (blog)
Factbox - U.S. biotech shares outpace broader stock market - 4-traders (press release)

REGENERON PHARMACEUTICALS INC : Regeneron and Bayer Report ...

Thu, 06 Jun 2013 06:36:43 GMT

REGENERON PHARMACEUTICALS INC : Regeneron and Bayer Report ...
4-traders (press release) - Jun 6, 2013

TARRYTOWN, N.Y., June 06, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for EYLEA(®) (aflibercept) Injection from the Phase 3 MYRROR study in myopic ...

Regeneron and Bayer say Eylea meets new study goal - Tbo.com
Regeneron: Study Shows Eylea Improves Vision Acuity in Retina Disease - Lloyd's List

Regeneron Pharmaceuticals, Inc. Presents at 38th Annual Deutsche Bank ...

Wed, 29 May 2013 17:21:57 GMT

Regeneron Pharmaceuticals, Inc. Presents at 38th Annual Deutsche Bank ...
Seeking Alpha - May 29, 2013

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 38th Annual Deutsche Bank Health Care Conference May 29, 2013 8:40 AM ET.

Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare ...

Mon, 20 May 2013 17:53:25 GMT

Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare ...
Seeking Alpha - May 20, 2013

Murray A. Goldberg - Chief Financial Officer, Senior Vice President of Finance & Administration and Assistant Secretary. Analysts.

Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8%

Thu, 23 May 2013 18:05:04 GMT

Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8%
Forbes - May 23, 2013

Investors eyeing a purchase of Regeneron Pharmaceuticals, Inc. (NASD: REGN) shares, but tentative about paying the going market price of $256.05/share, might benefit from considering selling puts among the alternative strategies at their disposal.